Novo Nordisk Stock Drops After Obesity Drug Trails Lilly’s Zepbound in Trial
.png)
Novo Nordisk Shares Fall After Obesity Drug Trails Lilly Rival 🚨 Breaking News: Novo Nordisk Stock Slides After Obesity Drug Misses Rival — Can It Catch Up to Lilly? Breaking News 🚨 Shares of Novo Nordisk dropped sharply after trial data showed its next-generation obesity drug underperformed Eli Lilly ’s blockbuster treatment. Why it matters: the $100B weight-loss market is heating up — and leadership may be shifting. Click here 💻 Download Free Softwares 2026 | Best Tools for Windows & Mac – 100% Safe & Updated!** 📰 What Happened? Novo Nordisk released late-stage trial results showing its experimental obesity drug CagriSema helped patients lose about 23% of their body weight over 84 weeks . However, Eli Lilly’s competing drug Zepbound achieved roughly 25% weight loss in a comparable study — a difference analysts say could significantly impact market share. Following the data release, Novo’s shares fell as investors questioned the drug’s commercial appeal. C...